CO-VANTAGE-DATA-CENTERS
11.4.2024 12:01:30 CEST | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced that it will open a second Zurich campus (ZRH2) this summer. The highly-secure and carrier-neutral campus will provide 24MW of critical IT capacity, and when combined with Vantage’s flagship Zurich campus (ZRH1), both campuses will offer customers 64MW of capacity for their computing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411671392/en/
Vantage Data Centers is developing 24MW ZHR2 campus located in Glattfelden just outside of Zurich, Switzerland. (Photo: Business Wire)
This campus, the company’s 33rd globally, is located 30 kilometers north of Zurich’s City Center in Glattfelden. It is conveniently situated just over 20 kilometers from Vantage’s ZRH1 campus in Winterthur and 15 minutes from Zurich Airport.
ZRH2 will have a total of 226,000 square feet (21,000 square meters) of space for Vantage’s customers consisting of hyperscalers, cloud providers and large enterprises. It comes online as the company is seeing increased demand globally to support artificial intelligence and other high-performance computing applications.
“Zurich is a rapidly growing data center market due to its strategic central location and its global financial leadership, and we expect to continue developing in this market based on customer demand,” said David Howson, president of Vantage Data Centers, EMEA. “Across Europe and the globe, the demand for highly efficient, hyperscale data centers is booming to meet the needs of next generation applications, from powerful AI models to high-performance computing and cloud transformation. Vantage is prepared to meet that demand for current and new customers, and we look forward to opening the doors of our latest data center this summer.”
Vantage Data Centers has committed to achieving net zero carbon emissions across its global portfolio by 2030 with a holistic approach to environmental sustainability. In line with the company’s “Sustainable by Design” blueprint, ZRH2 will deliver industry-leading power usage effectiveness (PUE) and water usage effectiveness (WUE) to support energy-efficient operations.
As a responsible corporate citizen who is committed to being a good neighbor, Vantage has installed air source (ASHP) and water source (WSHP) heat pumps within ZRH2. These heat pumps will convert waste heat for use to condition administrative spaces and reduce external energy use. ZRH2 will also provide waste heat to a nearby hotel and seminar center.
Additionally, ZRH2 will leverage rainwater infiltration and a green roof to minimize environmental impacts. It will feature a unique wood-finished facade, highly durable to withstand the local environment's harsh seasons and align with the look and feel of the community.
Vantage will employ more than 400 individuals during peak construction and create approximately 25 jobs to operate the campus.
To learn more about Vantage’s growing presence across EMEA, please visit: https://vantage-dc.com/data-center-locations/emea.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411671392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom